Kornimate/medical-research-clean huggingface dataset:
therapeutic education by telemedicine in chronic heart failure

Conditions: Heart Failure

Summary: the purpose of the sedic study is to test a home based heart failure patient clinical follow-up and therapeutic education using telemedicine. this educational follow-up is based on an interactive information system (scad) including a touch screen personal computer for heart failure patient at home. an interactive algorithm has been developed to allow a self management teaching to the patient.furthermore, a specialized nurse provide a clinical data follow-up.


Eligibility criteria:
inclusion criteria: * patients \> 65 years old hospitalized for acute heart failure * left ventricle systolic dysfunction with ejection fraction \< 45 %, documented in the previous 6 months * and at least one of the following criteria: bnp before discharge from hospital \> 350 pg/ml / ef \< 35 % / hospitalization for acute heart failure informed in the previous 6 months exclusion criteria: * nyha 4 at hospital discharge * planned cardiac surgery or coronary revascularization * hospitalization for st-elevation acute coronary syndrome * depressive syndrome with score \> 20 at geriatric depression scale * therapeutic education impossible * technical problems with the device * limited autonomy for device use * patient not living in basse-normandie * ongoing participation in another clinical trial
long term extension study in patients with primary hyperoxaluria

Conditions: Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases; Urologic Diseases; Genetic Disease; Primary Hyperoxaluria Type 3 (PH3)

Summary: the proposed study is designed to provide patients previously enrolled in phase 1 and 2 studies of dcr-phxc and their siblings (\<18 years old) long-term access to dcr-phxc, and to evaluate the long-term safety and efficacy of dcr-phxc in patients with ph.


Eligibility criteria:
key inclusion criteria: •participant successfully completed a dicerna pharmaceuticals, inc. study of dcr phxc. or participant is the sibling of a participant who successfully completed a dicerna pharmaceuticals, inc. study of dcr phxc. siblings must be younger than 18 years of age and must have genetically confirmed ph. * for participants rolling over from a multidose study of dcr-phxc, enrollment should occur within a window of 25 to 75 days from the last dose of study intervention. * estimated gfr at screening ≥ 30 ml/min normalized to 1.73 m2 body surface area (bsa), calculated using chronic kidney disease epidemiology collaboration (ckd epi) formula in participants aged ≥ 18 years, or the multivariate equation by schwartz in participants aged 12 months to 17 years. in japan, the cystatin c-based uemura formula will be used for participants aged 12 months to \<2 years, the creatinine-based uemura formula by will be used for participants aged 2 to 17 years, and the equation by matsuo will be used in participants aged ≥ 18 years. key exclusion criteria: * renal or hepatic transplantation (prior or planned within the study period) * plasma oxalate \> 30 µmol/l * currently on dialysis * documented evidence of clinical manifestations of systemic oxalosis

Keywords: primary hyperoxaluria ph1 ph2 rnai galnac ldha ldh sirna ph3
health eheart biobank

Conditions: Heart Diseases; Cardiac Diseases; Vascular Diseases; Cardiovascular Diseases

Summary: the purpose of the health eheart biobank is to collect and store specimen (e.g. blood, dna, tissue) for future studies at the university of california, san francisco (ucsf) that will help determine changes and identify molecular and genetic markers in the human body that might help increase our knowledge of heart disease and guide development of new diagnostic tools and treatments that may help rapidly detect heart disease and prevent and/or treat heart disease.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years or older. and at least one of the following: * established patient seen at ucsf and/or is a current participant in a clinical study that utilizes the heh biobank for biospecimen collection. * family member of a patient with cardiovascular disease. * patient with no cardiovascular disease. exclusion criteria: * unwilling to consent to biospecimen collection through the heh biobank.

Keywords: heart disease cardiovascular disease cardiology
omega-3 fatty acid-based parenteral nutrition improves postoperative recovery for cirrhotic patients with liver cancer

Conditions: Liver Cancer; Cirrhosis

Summary: the safety and efficacy of ω-3 fatty acid in patients with liver cancer followed hepatectomy is not known. this study provided evidences that ω-3 fatty acid-based parenteral nutrition improved postoperative recovery for cirrhotic patients with liver cancer underwent hepatectomy..

a new lipid emulsion enriched ω-3 fatty acid was manufactured, and was reported avoid hyperinflammatory situations in patients followed major surgery. however, the role of ω-3 fatty acid-based parenteral nutrition for postoperative patients with cirrhosis-related liver cancer is unclear. this study aims to evaluate the safety and efficacy of ω-3 fatty acid-based parenteral nutrition for cirrhotic patients with liver cancer followed hepatectomy. a prospective randomized controlled clinical trial was conducted for cirrhotic patients with liver cancer underwent hepatectomy between march 2010 and september 2013 in the investigators institution. for postoperative parenteral nutrition, 20% structolipid and 10% omegaven were applied to the trial group, while only structolipid to the control group for 5 consecutive days postoperatively.

Eligibility criteria:
inclusion criteria: * the cirrhotic malnourished patients who were diagnosed as liver cancer preoperatively and underwent hepatectomy were consecutively enrolled. exclusion criteria: * contraindication for hepatectomy, including gastrointestinal hemorrhage, severe hemorrhagic disorders, explicit acute nonspecific infectious lesion, overt ascites, child-pugh score c, indocyanine green retention rate at 15min (icgr15)\>30%(12), serum hepatitis b virus (hbv)-dna\>126 copies/ml and serum alanine aminotransferase (alt) \> 2×uln, serum triglycerides\>2.0 mmol/l, circulatory shock, stroke, acute myocardial infarction, renal failure, coma of unknown cause * pregnancy * age of\ 75y * performed intraoperative ablation * unresectable tumor during operation * allergic reactions against fish or egg proteins

Keywords: omega-3 progression parenteral nutrition
sudden hearing loss multi-center clinical trial

Conditions: Full-frequency Sudden Hearing Loss

Summary: the incidence of sudden hearing loss is rising obviously resent year, glucocorticoids have obtained obvious effect in the treatment of sudden deafness. postauricular hypodermic injection is the latest findings in clinical work and a new noninvasive way of administration which is gradually expanding research. the aim of this experiment is to verify and explore the efficacy and safety of the postauricular injection treatment with different doses of glucocorticoids.


Eligibility criteria:
inclusion criteria: * older than 18 years, less than 60 years old; * patient with unilateral or bilateral（occured successively) acute sensorineural hearing loss(asnhl) with onset 72hours or less ago. mean hearing loss compared with the unaffected contralateral ear of at leat 60 db; * primary presentation within 2weeks; standard treatment for 2 weeks; * after 2weeks of standard treatment, sensorineural hearing loss (shl) curative effect evaluation damaged frequencies \>/=30 db better than before; * written informed consent before participation in the study. exclusion criteria: systemic disease * history of tuberculosis or positive purified protein derivative (ppd); * insulin-dependent diabetes mellitus; * hypertension, poor control of bp(sbp/dbp)\>=140mmhg); * history of rheumatic disease, e.g. rheumatoid arthritis, scleroderma, lupus, etc; * serious psychiatric disease or psychiatric reaction to corticosteroids; * history of heart disease or transient ischemic attacks(tias); * prior treatment with chemotherapeutic or immunosuppressive drugs; * pancreatitis; * active peptic ulcer disease or history of gastrointestinal bleeding; * history of hiv, hepatitis b or c; * chronic kidney failure; * alcohol abuse; * active shingles; * severe osteoporosis or non-surgical aseptic necrosis of the hip; * without contraindication with glucocorticoid, ginaton, batroxobin. otologic disease * history of meniere's disease; * history of chronic ear infection; * prior history of sudden sensorineural hearing loss (ssnhl); * history of fluctuating hearing loss.

Keywords: full-frequency sudden hearing loss post auricular injection glucocorticoid multi-center
medicinal vs. orthotic comparison for migraine prevention: a double-blind study

Conditions: Migraine

Summary: to understand the impacts of using a fixed orthotic facial exercise appliance (blafit®) for migraine reduction, as compared to medication (fremanezumab-vfrm) and control.

the investigators will be studying the impacts of using an orthotic facial exercise device (blafit®) in the prevention of migraines for those who suffer from roughly 10-15 migraines per month. in order to test the efficacy of this device and its exercise routine, investigators will have one arm of our study receive the blafit® device and perform the exercises for one minute daily for three months. in arm #2, there will be another treatment: ajovy® (fremanezumab-vfrm) injections- which is a known and commonly practiced clinical prevention treatment for migraine patients. patients in this arm will receive three injections of ajovy, which is will be meant to last 3 months. in addition, investigators will have a placebo group that will receive three saline injections, which are meant to mimic the three ajovy® injections. arms #2 and #3 of this study will be conducted in a double-blind fashion, as both the clinician providing the injections and the patients receiving the injections will not know if the injecting substance is ajovy or saline, so as to minimize bias. all patients in all three months will log their number and pain level of their migraines each day for three months. upon conclusion, they will meet with our in-house neurologist (principal investigator \& sponsor) for a final in-person evaluation and questionnaire. results from the three groups will then be analyzed.

Eligibility criteria:
inclusion criteria: * those eligible to participate must be between the ages of 18 to 55 years. * the individual must experience at least 2 migraines per week. * they must be capable of visiting the medical facility in manhattan beach, california where the in-person screening and final evaluation will be conducted (following covid-19 public health guidelines). * they must be able to communicate with the study team via any teleconferencing service such as zoom, google hangouts, or facetime. exclusion criteria: * patients must not have any intracranial pathology, neurological or psychological conditions, epilepsy, cancer, any history of chemotherapy, hospitalized for depression, psychiatric conditions, seizures, or tumors. * patients cannot have taken botox® for migraine treatments. * patients cannot have had a history of head or neck surgery. * patients cannot be taking: propranolol, amitriptyline, flunarizine, topiramate, combination, galcanezumab-gnlm, fremanezumab-vfrm, or erenumab-aooe. * patients must not be deemed a vulnerable subject (including but not limited to: children, prisoners, pregnant women, mentally disabled persons).

Keywords: migraine ajovy facial exercise fremanezumab-vfrm
a study to evaluate the efficacy and safety of boceprevir added to standard of care therapy in previously treated participants with chronic hepatitis c genotype 1 and cirrhosis (mk-3034-105)

Conditions: Hepatitis C

Summary: this study is being done to find out if the addition of boceprevir to standard of care (soc) treatment with peginterferon alfa-2b (pegifn-2b) + ribavirin (rbv) is effective for participants with chronic hepatitis c (chc) genotype 1 and cirrhosis who were not successfully treated by previous soc. all participants will receive treatment with soc alone for 4 weeks and then boceprevir will be added to the treatment regimen for 44 additional weeks of combined treatment.


Eligibility criteria:
inclusion criteria: * weight between 40 kg and 125 kg * documented chc genotype 1 infection * previous course of treatment with soc (pegifn-2a or pegifn-2b + rbv) with a documented non-response * documented diagnosis of cirrhosis * no evidence of hepatocellular carcinoma (hcc) by ultrasound * participant and partner of participant must agree to use 2 effective contraceptives as specified for at least 2 weeks prior to day 1 of treatment and continue until at least 6 months after last dose of study drug (7 months for male participants) exclusion criteria: * co-infection with human immunodeficiency virus (hiv) or hepatitis b virus * use of any investigational drugs within 30 days prior to study enrollment * participation in any other clinical trial within 30 days of study enrollment or intention to participate in another clinical trial during this study * evidence of present or previous decompensated liver disease including, but not limited to, a history or presence of clinical ascites or hepatic encephalopathy. only participants with large (f3) esophageal varices, as determined in an esophagogastroduodenoscopy (egd) performed within the past 12 months according to international guidelines will be excluded. * clinically significant ocular examination findings * pre-existing significant psychiatric condition(s) * clinical diagnosis of active or recent substance abuse * evidence of active or suspected malignancy, or a history of malignancy, within the last 3 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin)
sgb reduces the incidence and severity of csa-aki

Conditions: Stellate Ganglion Block

Summary: the incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. stellate ganglion blocks increase renal blood flow, reduce inflammation and stress, and protect the heart muscle. in this study, stellate ganglion block was used to promote rapid recovery of kidney function after cardiopulmonary bypass cardiac surgery.


Eligibility criteria:
inclusion criteria: 1. patients of any gender were eligible provided they were between the ages of 18 and 80 years; 2. american society of anesthesiologists (asa) class of ⅲ or iv. exclusion criteria: 1. emergency cardiac surgery； 2. major vascular surgery； 3. non-sinus rhythm, reoperation； 4. contraindications for tee or sgb； 5. abnormal preoperative renal function； 6. severe preoperative heart failure with left ventricular ejection fraction \&lt; 30%, multi-organ dysfunction； 7. and severe infection requiring continuous antibiotic treatment; 8. enrolled in another clinical trial. elimination criteria: 1. incomplete follow-up data; 2. withdrawal during the procedure; 3. sgb failure or complications; 4. insufficient ultrasonographic imaging of the left renal artery on tee; 5. repeated cpb during surgery; 6. need for cardiac assist devices (extracorporeal membrane oxygenation, intra-aortic balloon pump, or ventricular assist devices) after cpb completion.

Keywords: stellate ganglion block cardiac surgery acute kidney injury sympathetic nerve renal artery resistance index
a d2 receptor occupancy and fmri study in schizophrenic subjects treated with lurasidone

Conditions: Schizophrenia

Summary: the purpose of this research study is to measure how many of the dopamine receptors lurasidone occupies throughout the brain of patients with schizophrenia or schizoaffective disorder and over what time period the occupancy occurs. this is research because lurasidone is an investigational medication that has not yet been approved by the food and drug administration (fda). dopamine receptors have key roles in many processes, including the control of motivation, learning, and fine motor movement. the degree of occupancy and the transience of occupancy d2 receptor occupancy for optimal clinical response and to prevent relapses is a controversial area that this study will address. in this study positron emission tomography (pet) scanning will be performed with d2/d3 ligand 18f-fallypride (a radioactive, injectable substance) to help the researchers measure the use of these receptors. researchers hope that quantifying the amount of receptors being occupied by the medication will help them to determine the best dose of study medication in terms of improvement and least side effects related to body size and gender as well as in preventing relapse that may be related to hypersensitivity. magnetic resonance imaging (fmri) will also be performed. mri is a scanning method which makes pictures of parts of the brain using a large magnetic field. this study will use a particular kind of mri called fmri, or functional mri. fmri takes pictures of the brain while the person is thinking or doing a simple task. fmri will allow the researchers to investigate patients regional brain activation during cognitive (mental) and emotional tasks.


Eligibility criteria:
inclusion criteria: subjects are eligible to participate in this study if they: * are 18 to 60 years of age at the day of first dosing. * are diagnosed with schizophrenia or schizoaffective disorder. * are female, subject must be using an acceptable method of birth control or be surgically sterile or postmenopausal. postmenopausal is defined as no period for at least 12 months. acceptable methods of birth control include oral, injectable or implanted contraceptives, and barrier methods such as condoms, diaphrams, and spermicides. * are able to provide written informed consent. * can safety have an mri (no metal in the body, not claustrophobic). exclusion criteria: subjects are not eligible to participate in this study if they: * are treatment resisitant or intolerant to lurasidone. * have had extensive radiation exposure (the study doctor will discuss this with the subject). * if they have tremors or shaking of the limbs. * are pregnant or trying to become pregnant or breastfeeding. * are colorblind. * have a current or past history of a major medical illness or have abnormal lab values which the study doctor feels is significant (any abnormal lab values will be discussed with the subject). * are taking certain medications. the study doctor will discuss these medicines with the subject. * have a history of alcohol, cannabis or cocaine abuse within two weeks prior to the study.
digital rectal exam proficiency tool

Conditions: Prostatic Hyperplasia; Prostate Cancer

Summary: a digital rectal exam proficiency tool, titled the 'direct' was developed based on the consensus of 10 experts. the purpose of this study is to validate this tool for use in both undergraduate and graduate medical education .

first, it will be validated on 120 anesthetized patients undergoing prostate surgery, comparing responses on the digital rectal exam clinical tool (direct) from both expert and novice clinicians, with surgical pathology reports. the second phase of validation will involve the participation of standardized patients, medical students and muta (medical urology teaching associate). during a standardized patient exercise focusing on digital rectal exam in the university of virginia school of medicine curriculum, 160 second-year medical students will be given the direct to document their examination. an attending physician will also attend the standardized patient exercise and document their examination for comparison with the medical students. the third phase includes 8 residents and up to10 attendings in the urology clinic, who will independently complete the direct documenting their dre in the course of usual care. comparison of faculty and student/trainee responses in all phases will be used for validation of the clinical tool for further use in medical education.

Eligibility criteria:
inclusion criteria: subjects who are patients: * patients who are male and adults ≥ 30 years of age * standardized patients between the ages of 30-80 years participating in the university of virginia school of medicine activity for second-year students learning digital rectal exams subjects who are clinicians: • attending physician, resident physician, or medical student scrubbed in for a prostatectomy or cystectomy, seeing patients in urology clinic, or participating in the school of medicine activity for second year students learning digital rectal exams exclusion criteria: list the criteria for exclusion * patients who do not have a prostate * patients with previous pelvic/perineal surgery * previously enrolled in this study
oral and topical tranexamic acid for the treatment of melasma

Conditions: Melasma; Chloasma; Melanosis

Summary: tranexamic acid has been used for treating melasma due to its effect on decreasing the activity of tyrosinase and melanogenesis. this 3-arm clinical trial will asess the efficacy and safety of oral and topical tranexamic acid as monotherapy compared with topical hydroquinone for 12 weeks in adults with melasma. the primary outcome will be the percentage of reduction at 12-week period of mmasi and melanin index. the incidence of adverse effects will be reported at weeks 4, 8 and 12.

tranexamic acid has been used for treating melasma due to its effect on decreasing the activity of tyrosinase and melanogenesis. this 3-arm clinical trial will asess the efficacy and safety of oral and topical tranexamic acid as monotherapy compared with topical hydroquinone for 12 weeks in adults with melasma. one hundred and twenty patients will be recruited in 3 groups of intervention: group i with tranexamic acid at a dose of 250 mg bid orally, group ii with 5% topical tranexamic acid bid, group iii with 4% topical hydroquinone once daily. the primary outcome will be the percentage of reduction at 12-week period of mmasi and melanin index. the incidence of adverse effects will be reported at weeks 4, 8 and 12.

Eligibility criteria:
inclusion criteria: * age older than 18 years * moderate to severe melasma * history of multiple topical depigmenting treatments and use of photoprotection, with subjective improvement less than 50% or mmasi \<50% reported by the dermatologist after one year of treatment. exclusion criteria: * pregnancy * hormonal contraception * lactation * treatment with hydroquinone or tranexamic acid at the time of the study or in the last 3 months * endocrinology diseases * hormone replacement therapy * family or personal history of one of the following: autoimmune disorders, coagulation disorders, chronic venous insufficiency, heart diseases, retinopathies, kidney disorders * mental disability

Keywords: melasma chloasma melanosis tranexamic acid hydroquinone therapeutics